TD Cowen analyst Yaron Werber has maintained their bullish stance on CLDX stock, giving a Buy rating on May 6.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Yaron Werber has given his Buy rating due to a combination of factors that highlight Celldex’s promising developments and potential in the pharmaceutical field. The upcoming 76-week data for the CSU trial is expected to provide critical insights into the durability of patient responses after treatment cessation, which could significantly enhance the attractiveness of barzolvolimab to dermatologists and allergists. This data is crucial as it may demonstrate the drug’s ability to maintain efficacy while minimizing adverse effects, thereby broadening its appeal.
Furthermore, the company’s ongoing and upcoming trials, including Phase 3 for CSU and CIndU and Phase 2 for PN, AD, and EoE, indicate a robust pipeline that could drive future growth. The anticipated data for EoE in the second half of 2025 is particularly noteworthy, as it targets an often-overlooked indication. Additionally, Celldex’s strong cash position of $673 million provides a solid financial runway to support these initiatives. These factors collectively underscore the potential for sustained disease control and justify the Buy rating.
According to TipRanks, Werber is a 4-star analyst with an average return of 7.6% and a 49.51% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Argenx Se, and Ascendis Pharma.
In another report released on May 6, LifeSci Capital also maintained a Buy rating on the stock with a $74.00 price target.